Use of Ezetimibe in Australia
Presentation
Paper/Presentation Title | Use of Ezetimibe in Australia |
---|---|
Presentation Type | Presentation |
Authors | Hollingworth, Samantha A., Ostini, Remo, Michael, David, Martin, Jennifer and Susan, Tett |
Journal or Proceedings Title | Pharmacoepidemiology and Drug Safety |
Journal Citation | 23, pp. 130-131 |
Article Number | 244 |
Number of Pages | 2 |
Year | Oct 2014 |
Place of Publication | United Kingdom |
ISSN | 1053-8569 |
1099-1557 | |
Digital Object Identifier (DOI) | https://doi.org/10.1002/pds.3701 |
Web Address (URL) of Paper | https://onlinelibrary.wiley.com/doi/10.1002/pds.3701 |
Conference/Event | 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (2014) |
Event Details | 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (2014) Delivery Online Event Date 24 to end of 27 Oct 2014 Event Location Taiwan |
Abstract | Background: Ezetimibe reduces absorption of dietary and biliary cholesterol by inhibiting its transport across the intestinal wall. Ezetimibe receives public subsidy in Australia from the Pharmaceutical Benefits Scheme (PBS) for very restricted indications (authorisation required). Objectives: To analyse the subsidised utilisation of ezetimibe in Australia. Methods: Utilisation of the five ezetimibe products (individual and combined with simvastatin) between 2004 and Results: Ezetimibe as a sole active ingredient was the most commonly dispensed formulation (0.25 up to 4.19 DDD/1000/day, from 2004 to 2012), followed by the two combination products containing ezetimibe and higher doses: 40 mg (0.21 up to 1.50 DDD/1000/day from 2006 to 2012); and 80 mg (0.16 up to 1.39 DDD/1000/day from 2006 to 2012) of simvastatin. The two Conclusions: Ezetimibe use has increased rapidly in Australia since receiving public subsidy. Although the indications for subsidy are very restricted there appears to have been quite widespread use, with total use of ezetimibe in all forms at 7.40 DDD/1000/day by 2012. Latest guidelines still question the value of ezetimibe use so further investigation is needed in Australia about whether the public spending on this medication is justifiable for the potential improvement in population health outcomes. |
Keywords | Ezetimibe; Australia |
Public Notes | Files associated with this item cannot be displayed due to copyright restrictions. |
Byline Affiliations | University of Queensland |
Library Services |
https://research.usq.edu.au/item/wv355/use-of-ezetimibe-in-australia
47
total views0
total downloads0
views this month0
downloads this month